EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer

被引：0
|
作者：
Roderich E. Schwarz
Niranjan Awasthi
Srivani Konduri
Danielle Cafasso
Margaret A. Schwarz
机构：
[1] UT Southwestern Medical Center,Department of Surgery, Division of Surgical Oncology
[2] UT Southwestern Medical Center,Department of Pediatrics, Division of Pediatric Critical Care Medicine
[3] The Cancer Institute of New Jersey,Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Divisions of Surgical Oncology and Surgical Sciences
来源：
Annals of Surgical Oncology | 2010年 / 17卷
关键词：
Vascular Endothelial Growth Factor; Proliferate Cell Nuclear Antigen; PDAC Cell; ASPC Cell; Tumor Tissue Section;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1442 / 1452
页数：10
相关论文
共 50 条
  • [31] Therapeutic effect of everolimus (RAD001) in combination with antiangiogenic chemotherapy for gastric cancer in vivo
    Cejka, D.
    Preusser, M.
    Sieghart, W.
    Strommer, S.
    Werzowa, J.
    Fuereder, T.
    Wacheck, V.
    EJC SUPPLEMENTS, 2006, 4 (12): : 25 - 25
  • [32] Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
    Daniel Ansari
    Roland Andersson
    World Journal of Gastroenterology, 2012, (35) : 4944 - 4958
  • [33] Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
    Sun, Chen
    Ansari, Daniel
    Andersson, Roland
    Wu, De-Quan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (35) : 4944 - 4958
  • [34] Synergistic effects and mechanism of Danshen injection in combination with chemotherapy and antiangiogenic therapy for colon cancer
    Guan, Zhonghai
    Lan, Huanrong
    Chen, Xiangheng
    Jiang, Xiaoxia
    Li, Zhongqi
    Yu, Xiongfei
    Cao, Jiang
    Jin, Ketao
    Teng, Lisong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (04): : 6437 - 6444
  • [35] A New, Multifaceted STRIDE II-Based Monitoring Protocol for Advanced Therapy Starts in Inflammatory Bowel Disease
    Mackay, Scott
    Parsons, Denise
    Hoentjen, Frank
    Dieleman, Levinus
    Gozdzik, Michal
    Kroeker, Karen
    Wong, Karen
    Mcmullen, Todd
    Peerani, Farhad
    Halloran, Brendan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S926 - S927
  • [36] A phase II irinotecan–cisplatin combination in advanced pancreatic cancer
    C Markham
    D D Stocken
    A B Hassan
    British Journal of Cancer, 2003, 89 : 1860 - 1864
  • [37] Multicenter Phase II Study of Gemcitabine and S-1 Combination Therapy (GS Therapy) in Patients With Metastatic Pancreatic Cancer
    Ueno, Hideki
    Okusaka, Takuji
    Furuse, Junji
    Yamao, Kenji
    Funakoshi, Akihiro
    Boku, Narikazu
    Ohkawa, Shinichi
    Yokosuka, Osamu
    Tanaka, Katsuaki
    Moriyasu, Fuminori
    Nakamori, Shoji
    Sato, Tosiya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (08) : 953 - 958
  • [38] A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer
    Ueno, H.
    Okusaka, T.
    Furuse, J.
    Yamao, K.
    Funakoshi, A.
    Boku, N.
    Ohkawa, S.
    Makimoto, A.
    Sato, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer
    Zhao, Ming
    Tominaga, Yohei
    Ohuchida, Kenoki
    Mizumoto, Kazuhiro
    Cui, Lin
    Kozono, Shingo
    Fujita, Hayato
    Maeyama, Ryo
    Toma, Hiroki
    Tanaka, Masao
    CANCER SCIENCE, 2012, 103 (01): : 58 - 66
  • [40] Hybrid-nanoengineering of an effective combination therapy for pancreatic cancer
    Singh, Mewa
    Briggs, Michael R.
    CANCER RESEARCH, 2020, 80 (16)
12345